Navigation Links
Vallon Holdings, LLC Launches New Subsidiary Focused on Contract Resources for the Minneapolis-St. Paul Life Science Industry
Date:2/29/2008

MINNEAPOLIS, Feb. 29 /PRNewswire/ -- Vallon Holdings, LLC, a Minneapolis-based privately-held holdings company, has launched Vallon LifeScience, a new professional services subsidiary providing experienced interim and contract resources to Minneapolis-St. Paul life science companies.

"Vallon LifeScience is a breakthrough in one of the key problems facing life science companies today," states Paula J. Norbom, President and Founder of Vallon LifeScience. "...how to rapidly find the best and most experienced industry talent to continue driving your business forward."

Minneapolis-St. Paul is a prolific market for medtech, biotech, pharmaceutical and healthcare companies. Vallon LifeScience and their deep network of talent, is uniquely equipped to meet the increasing demands for highly specialized interim and contract professionals. Doug Ruth, CEO of Vallon Holdings, LLC, states, "Our new LifeScience subsidiary will give companies immediate access to talented life science resources that will help them meet operational, product development, commercialization and strategic challenges."

For an industry that features distinct challenges in getting products to market, Vallon LifeScience is offering a remarkable solution without the same hassles of working with a typical consulting or staffing firm. "We quickly provide our clients with the best-matched professional to grow their businesses," states Norbom. "When you know the right people, it's that simple."

In addition to the launch, the firm unveiled a new web site for Vallon LifeSciences which can be viewed at http://www.vallonlifescience.com.

About Vallon Holdings, LLC.

Vallon Holdings, LLC is a privately-held holdings company with two subsidiaries: Vallon LifeScience, LLC that provides contract resources for the life science industry and Vallon LLC that provides companies with experienced executives for project and
'/>"/>

SOURCE Vallon Holdings, LLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. NightHawk Radiology Holdings, Inc. Announces Board Member Departure
2. NightHawk Radiology Holdings, Inc. to Speak at the Cowen and Company 28th Annual Health Care Conference on March 18, 2008
3. Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
4. Platinum Underwriters Holdings, Ltd. Reports Record Fourth Quarter and Year Ended December 31, 2007 Financial Results
5. NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance
6. Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC
7. NightHawk Radiology Holdings, Inc. Announces Time Change for Fourth Quarter and Full-Year 2007 Earnings Conference Call
8. MBF Healthcare Acquisition Corp. to Host Investor Conference Call to Review Stock Purchase Agreement Signed With Critical Homecare Solutions Holdings, Inc.
9. MBF Healthcare Acquisition Corp. Announces Signing of Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc.
10. NightHawk Radiology Holdings, Inc. Announces Date for Fourth Quarter and Full-Year 2007 Earnings Conference Call
11. China Pharma Holdings, Inc. Receives Chinese SFDA Approval for Generic Bumetanide Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2008)...ewswire/ -- The HealthCentral,Network, Inc. (http...pConnection.com, a new online medical and peer-to-...hose struggling with obesity about,drugs, surgerie...scuss and,post questions., Three expert writers, .... Jeffrey Heit, television health reporter Amy Hen...
(Date:7/9/2008)...n that would cut $39 million from,Medicare Advanta...Newswire-USNewswire/ -- Seniors across,Mississippi...icare,Advantage program in legislation being consi...31) would cut $39 million from the Medicare Advant...back the areas where Medicare,private fee-for-serv...
(Date:7/9/2008)...n that would cut $38 million from,Medicare Advanta...ewswire-USNewswire/ -- Seniors across New Mexico,a...are Advantage program in,legislation being conside...) would cut $38 million from the Medicare Advantag...k the areas where Medicare private,fee-for-service...
(Date:7/9/2008)...a larger role in kidney transplants than previousl... well in men due to their smaller size. Women hav...Therefore, in the future, gender should be conside...esearchers from Basel and Heidelberg. , These re...ve Transplant Study", the world,s largest database...
Breaking Medicine News(10 mins):Health News:Responding to Increased Incidence of Obesity and Associated Health Issues, The HealthCentral Network Launches Site to Support those Struggling with Weight 2Health News:Mississippi Seniors Speak Out Against Medicare Advantage Cuts 2Health News:New Mexico Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Male kidneys for men only? 2
...00 people across the UK suffering from liver disea...7,000, according to a report by the Health Protect...who suffer from the chronic hepatitis C infection,...ition. Injected drugs are believed to be responsib...
...for a ban on an artificial sweetener aspartame, wh...dicines, food and drinks.// He said that there was...ed in cereal, chocolate and cola, may cause cancer... reports that aspartame caused cancer in rats. Dos...
...lege and Research Institute (SRMC&RI), and Asia CR...a joint venture towards establishing an exclusive ...mbilical cord blood stem cells are reported to hol... of diseases. The focus of the new center will be ...
...'s disease is expected to rise due to changing lif...osion in developing nations. //As of 2005, 24 mill... to cardiovascular disease, and old age, and by th... to 42 million, and to 81 million by the year 2040...
Other Medicine News:
(Date:7/8/2008)...K, July 8 /- McGraw-Hill Professional...es for the scientific and medical,communities, tod...ectiveness reference to its comprehensive online p...//www.accesspharmacy.com ). Through an alliance wi...ases generated from clinical,studies, AccessPharma...
(Date:7/7/2008)...HCV Development Presence Includes ANA598 and ANA77...Complementary Mechanisms Conferen...- Anadys Pharmaceuticals,I...suming clinical,investigation of the Toll-Like Rec...nic hepatitis C. Based on preclinical pharmacology...
(Date:7/7/2008)...NG, July 7 /- OrbusNeich today announ...l Meeting of the Japanese Society of,Interventiona...eered R,stent has better outcomes when compared to...ione, M.D., the study,s principal,investigator and...ples,s,Division of Cardiology, Department of Clini...
(Date:7/6/2008)...e basis for CTI,s Marketing Authorization Applicat...by the EMEA, SEATTLE, July 7 /PRNewswire-FirstCal... ; MTA) today announced the publication of results...XIO(TM) (paclitaxel poliglumex,CT-2103) with gemc...performance status 2) patients with previously unt...
Breaking Medicine Technology:McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 3Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 4Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 5Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 2Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5Providence Holy Cross Medical Center Ignores Community Environmental Concerns With Planned Expansion of Mission Hills Facility 19133 1Providence Holy Cross Medical Center Ignores Community Environmental Concerns With Planned Expansion of Mission Hills Facility 19133 2Cardinal Health Completes Enturia Acquisition 2043 1Cardinal Health Completes Enturia Acquisition 2043 2Federal government taps NC State experts to explain nanotech risks 5330 1Federal government taps NC State experts to explain nanotech risks 5330 2Westaim announces 2008 first quarter results 19126 1Westaim announces 2008 first quarter results 19126 2Westaim announces 2008 first quarter results 19126 3
... 2007 /PRNewswire/ -- Prolexys,Pharmaceuticals and...erties of the selective small molecule anti-tumor ...company,s,chemi-proteomics technology to understan... to be published in the June 14, 2007 issue,of the...hondrial,voltage- dependent anion channels (VDACs)...
...07 /PRNewswire/ -- Two studies presented,today dem... peak,plasma levels, nor did it impair middle-of-t...n patients who suffer from chronic,insomnia. The r...nnual Meeting of the Associated Professional Sleep...ause they show that ROZEREM may be,a safe sleep me...
Other Medicine Technology:Prolexys Pharmaceuticals and Columbia University Researchers,Publish Study on Anti-Tumor Properties of a Selective Small,Molecule Anti-Tumor Agent With Novel Mechanism of Action 2Prolexys Pharmaceuticals and Columbia University Researchers,Publish Study on Anti-Tumor Properties of a Selective Small,Molecule Anti-Tumor Agent With Novel Mechanism of Action 3Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 2Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 3Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 4Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 5
The Reusable Template is designed for use with the Brachystepper® as a guidance system for prostate brachytherapy. Please be sure that the graphics on your software match the graphics on the Reus
The MicroTouch LP (low profile) is specifically designed for use on cystoscopy tables with a fixed fluoroscopy/x-ray gantry. The MicroTouch LP attaches to tables on the side opposite the gantry and a
The Precision Stepper is the first stepper with a fully adjustable baseline. This new technology permits the physician to fine-tune the depth of the ultrasound transducer for accurate imaging and pr
The specially designed table-mounted stepper/stabilizer offers the strength and stability necessary for a flawless delivery of brachytherapy.
Medicine Products: